FDA’s Center of Excellence to hold childhood cancer advocacy forum

by Gregory H. Reaman, MD

Do you want to learn more about approved drugs for childhood cancer and the approval process for cancer treatments?

Would you like to hear expert views from a variety of stakeholders on the feasibility of pediatric patient-reported outcomes to help facilitate new drug development?

Do you want to know more about how FDA helps pediatric patients in need gain access to experimental therapies and the plans for implementing new legislation that will impact cancer drug development for children?

If so, plan to attend or log on to the FDA Oncology Center of Excellence’s FDA Outreach to the Childhood Cancer Advocacy Community, scheduled for Friday, March 15, at FDA’s White Oak campus in Silver Spring, MD.

Interested parties can register to attend in person or participate remotely via livestream (following registration). Both options are available at no cost to participants.

Among other topics on the agenda, FDA officials will discuss various aspects of the Best Pharmaceuticals for Children’s Act relative to pediatric oncology drug development and provide information about how the FDA Reauthorization Act of 2017 affects development of pediatric oncology therapies.

For more information, please contact Christine Lincoln at christine.lincoln@fda.hhs.gov.

Gregory H. Reaman, MD, is associate director for oncology sciences in FDA’s Office of Hematology and Oncology Products, and associate director for pediatric oncology in the agency’s Oncology Center of Excellence.